Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China

• Үндсэн зохиолчид: Shi-Yuan Wang (Зохиогч), Shu-Zhen Liu (Зохиогч), Kai Chu (Зохиогч), Yue Zhao (Зохиогч), Feng-Cai Zhu (Зохиогч), Yue-Mei Hu (Зохиогч), Fan-Yue Meng (Зохиогч), Jing-Xin Li (Зохиогч), Li Luo (Зохиогч), Jia-Ying Yang (Зохиогч), Pei Liu (Зохиогч), Jun Yu (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Taylor & Francis Group, 2017-11-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: Viruses from two antigenically distinct influenza B strains have co-circulated since the mid-1980s, yet inactivated trivalent influenza vaccines (TIVs) with either the Victoria or Yamagata lineage could only provide limited protection from influenza B strain. Quadrivalent influenza vacci...